Abstract: Objective To evaluate the efficacy and toxicity of paclitaxel liposome or cisplatin concurrent chemoradiotherapy for locally advanced cervical carcinoma.Methods Forty-five patients with locally advanced cervical carcinoma（FIGO stage ⅠB2-ⅣA）were enrolled into the study and divided into paclitaxel group（n=26） and cisplatin group（n=19）. Radiotherapy included external three dimensional conformal radiotherapy（45Gy／25f） and 192Ir brachytherapy （30.36Gy／5.6f at point A）. In paclitaxel group， patients received paclitaxel liposome 55mg／m2 per week for 5 weeks， and others in cisplatin group received cisplatin 30mg／m2 per week for 5 weeks.The efficacy and toxicity in each group were compared. Results All patients finished concurrent chemoradiotherapy. In paclitaxel group， 13 cases achieved CR，10 PR，3 SD，and the response rate（RR） was 88.5％；in cisplatin group， 12 cases achieved CR，3 PR，3 SD，1 PD，and RR was 84.2％. The 1-year survival rate was 95.2％ and 89.5％ for paclitaxel group and cisplatin group， and 1-year progression-free survival rate was 92.3％ and 73.7％ respectively， but there was no significant difference between two groups（P＞0.05）. The toxicities in the two groups were mainly in grade 1-2， and the incidence of blood and gastrointestinal tract toxicities in paclitaxel liposome was lower than that of cisplatin group. Conclusion Paclitaxel liposome based and cisplatinbased concurrent chemoradiotherapy present a similar efficacy for locally advanced cervical carcinoma and the toxicities of paclitaxel liposome-based concurrent chemoradiotherapy is mild.